Background: Acute myocardial infarction (AMI) is an acute stress state in which plasma copeptin rises. The combination of copeptin and troponin has been suggested to improve the diagnostic performance of acute MI in chest pain patients at time of presentation in the emergency department.
Introduction
Initial evaluation for acute myocardial infarction (AMI) relies on 12-lead electrocardiography recording and biomarker analysis, in complement to clinical assessment [1] . Cardiac troponin (cTn) T and I are the standard markers for myocardial necrosis, and an elevation in cTn is considered as part of the universal definition of myocardial infarction [2] .
The adequate ruling out of acute coronary syndrome (ACS) in patients with chest pain is crucial, as the erroneous discharge of a patient with ACS is associated with a high risk of cardiac events [3] . Copeptin, a relatively novel biomarker, is the cterminal of the vasopressin precursor hormone and is cosecreted with the hormone [4] .
Normal plasma level of copeptin in healthy volunteers ranges between 1.0 and 14 pmol/L with a median value below 5.0 pmol/L. Its level in men is slightly higher than in women with a difference in median value by 1.0 pmol/L [5] .
There are no data supporting any fixed correlations between copeptin levels and common risk factors apart from dyslipidemia; however, the data on dyslipidemia are conflicting [6] [7] [8] .
Copeptin has a longer half-life than vasopressin; it is easier to detect and directly reflects vasopressin release. Copeptin, and thereby vasopressin, are released by endogenous stress and increase immediately after the onset of chest pain [9] . The combination of a marker of endogenous stress and a marker of cell necrosis can improve the diagnostic performance in patients with chest pain at the time of presentation in the emergency department [10] .
Patients and methods
This observational prospective study was conducted in Cairo University hospitals on 40 patients who presented to the critical care department with chest pain as a primary symptom of possible acute coronary syndrome.
Inclusion criteria
Any adult patient with an age P 18 years who presented with the following symptoms: , where the 99th, 97th, and 95th percentile cutoff values were 18.9 pmol/l, 13 pmol/l, and 9.8 pmol/l, respectively. Most clinical studies used a copeptin cutoff of 14 pmol/l. This cutoff was driven by the first copeptin assay available and is still used in most studies [11] .
Statistical methodology
Analysis of data was done by IBM computer using SPSS (statistical program for social science version [12] ).
Mean and SD were calculated for quantitative variables while number and percentage for were used to denote qualitative variables. Chi-square test was used to compare qualitative variables, and unpaired t-test was used to compare quantitative variables, in parametric data (SD < 50% mean). Mann-Whitney-Wilcoxon U test was used for nonparametric data. ROC curve (receiver operator characteristic) was used to find out the best cut-off value and validity of certain variable. Sensitivity and specificity tests were also used.
Results

Descriptive data
Demographic data
The age of the studied group ranged from 48 to 65 years with a mean of 56 ± 4.6 years. Thirty-four patients (85%) were males and 6 patients (15%) were females (Table 1) .
Risk factors
All patients had at least one risk factor. The most frequent risk factor was hypertension (82.5%) followed by dyslipidemia (62.5%), previous CAD (60%), diabetes mellitus (57.5%), smoking (45%), and +ve family history (20%) ( Table 1) .
ECG findings
The most frequent ECG changes were ST segment depression in 21 patients (52.5%), ST segment elevation in 15 patients (37.5%), and LBBB in only one patient (2.5%). No ECG changes were elicited in 3 patients (7.5%) ( Table 1) . 
Comparative data
Copeptin with risk factors and ECG changes
Our study showed a significant relation between high copeptin and dyslipidemic patients with a P-value of 0.041 and an insignificant relation with other risk factors. There was no significant relation between ECG and copeptin levels in the study group (Table 1) .
Copeptin with troponin in 6 h
Our study showed an insignificant correlation between troponin and copeptin in the first 6 h from the onset of chest pain ( Table 2 ).
The sensitivity of copeptin with troponin measured in 6 h is 100% while the specificity is 24.2%. Positive predictive value is 21.2%, and the negative predictive value is 100% (Table 3) .
Copeptin with troponin in 12 h
Our study showed a strong +ve correlation between serum levels of copeptin within 6 h from onset of chest pain and troponin after 12 h ( Table 4 ).
The sensitivity of copeptin with troponin measured in 12 h is 96.8% and the specificity is 87.5%. The positive predictive value of copeptin and troponin measured in 12 h is 96.8% while the negative predictive value is 87.5% (Table 5 ).
ROC curve of copeptin as a predictor of myocardial infarction
The receiver operator characteristic (ROC) curve was calculated for copeptin as a predictor for myocardial infarction (MI). The area under the curve (AUC) for copeptin to predict MI was 98% with confidence interval (CI) 0.94/1.0. The optimal cut-off value of copeptin to predict MI was 21.1 pg/ml with a sensitivity of 100% and specificity of 87.1%, and the overall accuracy was 93.5% with P value 0.001 ( Fig. 1 and Table 6 ).
Discussion
Copeptin is a novel neuroendocrine peptide that was recently introduced to the field of acute medicine biomarkers. In acute stress condition, copeptin rises and reflects stress level exactly like arginine vasopressin (AVP), which was largely known as a mediator of non-specific stress conditions beside its prominent role in water homeostasis.
In recent years, many studies reported that when copeptin is combined with cardiac troponins in diagnosis of patients presenting with acute chest pain in early hours, it accelerates early rule in of AMI and rule out of non-MI patients [12] .
In CHOPIN trial, one of the largest multicenter studies on consecutive patients with chest pain, only approximately 8% had a final gold standard diagnosis of AMI (STEMI and NSTEMI), whereas >60% had a non-cardiac origin of their symptoms. The results showed that the addition of copeptin allowed 58% of patients with non-diagnostic ECG to be ruled out for an AMI. The availability of copeptin at baseline reduced the time to decision for AMI diagnosis from an average of 3-1.8 h (43% reduction). Moreover, the combination of a negative troponin and negative copeptin value on presentation allows the rule out of AMI with a negative predictive value (NPV) > 99% [13] . Our results are in accordance with the CHOPIN study such that combining troponin and copeptin on presentation can rule out cases of AMI with NPV 100%.
Reichlin and Mu¨ller et al. reported the role of copeptin in the management of 487 patients with chest pain presenting to the emergency department (ED). This study described that in patients who were diagnosed as having acute MI, the copeptin levels were elevated 0-4 h after the onset of symptoms while troponin T was still undetectable in many patients [14] .
Our study shows a strong correlation between serum copeptin and troponin-I measured in 12 h (P = 0.001) while there was a poor correlation between serum copeptin and troponin-I in first 6 h (P = 0.18). This indicates that copeptin is increased early in the first 6 h before troponin has been increased, and both were high within 12 h from the presentation.
Our results are supported by many studies such as the study by Gu et al. who reported that cardiac troponin-T (cTnT) is raised within 6-9 h from the onset of symptoms with a sensitivity of 39-43% when the patient is admitted to the ED in the early three hours of onset. The addition of another biomarker, such as copeptin, to cTnT may be more informative in reflecting myocardial ischemia [15] .
Reichlin et al. measured cTnT, myocardial band of creatine kinase (CKMB), myoglobin and copeptin at the time of presentation, 3, 6 and 9 h later. They reported that plasma copeptin was higher than that of cTnT at the time of admission for patients with AMI. The cTnT level was below the detection PPV, positive predictive value; NPV, negative predictive value. limit of 0.04 lg/L in 35% patients at the presentation time.
Early ruling out of AMI at the presentation time was achieved by combining the results of copeptin assay of 614.0 pmol/L and cTnT assay of 60.01 lg/L with 98.8% sensitivity, 77.1% specificity, 99.7% NPV and 46.2% positive predictive value (PPV). Hence, the added value of copeptin to cTnT assay accelerated clinical decision for ruling out of non-AMI patients without the need for serial blood sampling for repeating cTnT measurement and prolonged monitoring time [14] .
Our study showed high sensitivity (100%) of copeptin with troponin measured in first 6 h and high NPV of copeptin with troponin-I measured in 6 h (100%). This finding may help in early ruling out of patients with AMI who presented in the first six hours from the onset of chest pain.
This in agreement with Bohyn et al. who tested a rule-out strategy using copeptin, high-sensitive troponin T, and the Global Registry of Acute Coronary Events (GRACE) score. They reported a NPV of 99% (95% confidence interval 94-100%) [16] . However the GRACE score was not included in our study and we measured troponin I.
In another study by Chenvier-Gobeaux et al., the cohort was divided into three pre-test-probability groups (low, medium, or high), as assessed by the treating ED physician after the first clinical evaluation but before the availability of the biomarker results. The NPVs of combined copeptin and cTnI for diagnosis of MI were 100% (78-100) in high-risk patients, 98% (87-100)% in medium-risk patients, and 100 (95-100) in low-risk patients [17] .
Another study by Ray et al., who investigated 451 patients with a previous history of CAD and negative cTn on admission, evaluated the additional value of copeptin to conventional cTn for a rapid ruling out of AMI in patients with acute chest pain and a previous history of CAD. In ED triage of patients with acute chest pain suggestive of a non-STsegment elevation AMI and a previous history of CAD, the combination of copeptin and cTnI allowed the clinicians to rule out AMI on presentation, with a NPV of 98% [18] .
In our study, the ROC curve was calculated for copeptin as a predictor for myocardial infarction. The AUC for copeptin to predict was 98% (CI = 0.94-1.0). The optimal cut-off value of copeptin to predict was 21.1 pg/ml with a sensitivity of 100% and specificity of 87.1%, and the overall accuracy was 93.5% with a P value of 0.001. Keller et al. evaluated different potential cut-off values for copeptin in a large reference population (n = 1386), where the 99th percentile cutoff value was 18.9 pmol/l, the 97.5th percentile value was 13 pmol/l, and the 95th percentile value was 9.8 pmol/l. Most clinical studies used a copeptin cut-off of 14 pmol/l. This cutoff was driven by the first copeptin assay available and is still used in most studies. The lower the cutoff value, the higher is the NPV for the diagnosis of AMI. To minimize the number of false-negative patients, a 95th percentile value (10 pmol/l) might be advisable [11] .
Piyanuttapull studied 150 patients with chest pain presented to the ED. He found that plasma copeptin level increased and correlated with troponin-T in the diagnosis of myocardial infarction (r = 0.317) at presentation. It further increased and correlated (r = 0.562) at six hours after presentation. Plasma copeptin levels for diagnosis of ST elevation myocardial infarction (STEMI) at presentation have an AUC of 0.91, sensitivity 90.9%, and specificity 87.8% with a p value < 0.001 [19] .
Our study was on conventional troponin I, which in comparison with the conventional troponin T, has no significant difference. Wu et al. who described that TnT and TnI have similar release kinetics from the damaged myocardium. Both troponins increase in serum within 4-9 h after AMI, peak at 12-24 h, and remain elevated for up to 14 days [20] . The difference can be significant if high-sensitive troponin T was used in the study instead of the conventional troponin T.
Limitations
Due to our limited resources, the sample size was small. The number of patients should be increased in a multi-center basis study.
Figure 1
The receiver operator characteristic (ROC) curve of copeptin. 
Conclusion
1. Combined measurements of troponin I and copeptin on admission early (within 6 h) after onset of chest pain provide a high NPV for acute MI. This combination might aid in early and safe rule-out of AMI. 2. Plasma copeptin cut-off level of 21.1 pg/ml might be used for early rule-in of myocardial infarction to be accurately diagnosed later by troponin measurement.
